Good point. I always conflate the 2 areas in my mind for some reason as they are pretty interlinked. Anyways it's business as usual with the article I quoted and TEVA will only pull the plug if results are negative on their early efficacy analysis anyways. We've already got them in so its a moot point.
What at is a more important issue is its about time MSB got another pharma deal with one of their other trials given they've been talking about "many interested parties" for ages.
Given their recent cent cash burn frankly they can't fund a 3rd p3 themselves. They have said a trearment of theirs for....spine? I forget is going to p3 before this year ends. I'd feel better if they announced it was in partnership with another pharma. Always looks better when another company comes onboard.
MSB 0_o, page-39
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |